Form 4: Amylyx Pharmaceuticals' Chief Medical Officer Sells Shares to Cover Tax Obligations

Camille L. Bedrosian, Chief Medical Officer of Amylyx Pharmaceuticals, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On March 31, 2025, Camille L. Bedrosian, the Chief Medical Officer of Amylyx Pharmaceuticals, sold 12,425 shares of common stock at a weighted average price of $3.4674.
• The sales were executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Bedrosian directly owns 194,375 shares of Amylyx Pharmaceuticals.
• The sales were automatic and not at the discretion of the reporting person.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing relates to a routine transaction for tax purposes. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This sale appears to be related to tax obligations, which is a common occurrence.

Stakeholder Impact

• The sale of shares by an insider could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates

Keywords

Amylyx Pharmaceuticals, AMLX, Camille L. Bedrosian, Chief Medical Officer, Form 4, Share Sale, Tax Withholding, Restricted Stock Units, Beneficial Ownership